Evidence map›Paper›PMID 24136332›Full record

Trial reportThe European respiratory journal2014

Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial.

Prescott G Woodruff, Wissam Chatila, John E Connett, Gerard J Criner, Jeffrey L Curtis, Mark T Dransfield, Meilan K Han, Stephen C Lazarus, Nathaniel Marchetti, Thomas J Rogers and 6 more

Abstract readLetterRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The European respiratory journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Anti-TNFα therapy in inflammatory lung diseases.Pharmacology & therapeutics · 2017
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Prescott G WoodruffUniversity of California, San Francisco, CA.
Wissam Chatila
John E Connett
Gerard J Criner
Jeffrey L Curtis
Mark T Dransfield
Meilan K Han
Stephen C Lazarus
Nathaniel Marchetti
Thomas J Rogers
Paul D Scanlon
Don D Sin
Helen Voelker
Christine Wendt
Richard K Albert
COPD Clinical Research Network

Funding

ZONA-FREE HAMSTER OVA ASSAY AS AN INDICATOR OF MALE FERTILITYM01RR000425 · NCRR · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI ANDERSON, GAIL V · 1985 to 2011
$74.2M
ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI KOSMISKI, LISA A. · 1985 to 2008
$52.6M
Zoledronic Acid in Treatment of Osteoporosis in PostmenoM01RR002635 · NCRR · BRIGHAM AND WOMEN'S HOSPITAL · PI GARBER, JUDY E. · 1985 to 2008
$48.4M
Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
COPD Clinical Research Network - Data Coordinating CenterU10HL074424 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI CONNETT, JOHN E · 2003 to 2011
$21.0M
Zonulin Antibodies in Intestinal Permeabilitiy in IDDMM01RR016500 · NCRR · UNIVERSITY OF MARYLAND BALTIMORE · PI OSWALD, LYNN M · 2002 to 2009
$20.2M
Novel Strategies Targeting Acute Exacerbation of COPDU10HL074409 · NHLBI · DENVER HEALTH AND HOSPITAL AUTHORITY · PI ALBERT, RICHARD K · 2003 to 2007
$4.1M
COPD Exacerbations: Pharmacogenetic Approaches to TherapyU10HL074428 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI WASHKO, GEORGE R · 2003 to 2007
$3.4M
UAB/BVAMC Clinical Center in COPDU10HL074418 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DRANSFIELD, MARK T · 2003 to 2007
$3.3M
Strategies to Improve COPD ManagementU10HL074407 · NHLBI · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI CASABURI, RICHARD · 2003 to 2007
$3.2M
COPD Clinical Research Network & Clinical Research Skills Core DevelopmentU10HL074408 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI CRINER, GERARD J · 2004 to 2007
$2.7M
NCATS NIH HHS UL1 TR001082NCRR NIH HHS M01 RR000051NCRR NIH HHS M01 RR000056NCRR NIH HHS M01 RR000425NCRR NIH HHS M01 RR002635NCRR NIH HHS M01 RR016500NCRR NIH HHS RR00051NCRR NIH HHS RR00056NCRR NIH HHS RR00425NCRR NIH HHS RR02635NCRR NIH HHS RR16500NHLBI NIH HHS 1U10-HL074416NHLBI NIH HHS 1U10-HL074424NHLBI NIH HHS 1U10-HL074431NHLBI NIH HHS HL074407NHLBI NIH HHS HL074408NHLBI NIH HHS HL074409NHLBI NIH HHS HL074418NHLBI NIH HHS HL074422NHLBI NIH HHS HL074428NHLBI NIH HHS HL074439NHLBI NIH HHS HL074441NHLBI NIH HHS U10 HL074407NHLBI NIH HHS U10 HL074408NHLBI NIH HHS U10 HL074409NHLBI NIH HHS U10 HL074416NHLBI NIH HHS U10 HL074418NHLBI NIH HHS U10 HL074422NHLBI NIH HHS U10 HL074424NHLBI NIH HHS U10 HL074428NHLBI NIH HHS U10 HL074431NHLBI NIH HHS U10 HL074439NHLBI NIH HHS U10 HL074441
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Bacterial AgentsAzithromycinDisease ProgressionHumansProportional Hazards ModelsPulmonary Disease, Chronic ObstructiveReceptors, Tumor Necrosis Factor, Type IIAnti-Bacterial AgentsAzithromycinReceptors, Tumor Necrosis Factor, Type IITNFRSF1B protein, human

Identifiers

PMID24136332
PMCPMC4326242

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.